[go: up one dir, main page]

AU2003302106A1 - New tricyclic angiotensin ii agonists - Google Patents

New tricyclic angiotensin ii agonists

Info

Publication number
AU2003302106A1
AU2003302106A1 AU2003302106A AU2003302106A AU2003302106A1 AU 2003302106 A1 AU2003302106 A1 AU 2003302106A1 AU 2003302106 A AU2003302106 A AU 2003302106A AU 2003302106 A AU2003302106 A AU 2003302106A AU 2003302106 A1 AU2003302106 A1 AU 2003302106A1
Authority
AU
Australia
Prior art keywords
agonists
new tricyclic
angiotensin
tricyclic angiotensin
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003302106A
Inventor
Mathias Alterman
Anders Hallberg
Kannan Mahalingam
Yiqian Wan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vicore Pharma AB
Original Assignee
Vicore Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma AB filed Critical Vicore Pharma AB
Publication of AU2003302106A1 publication Critical patent/AU2003302106A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/34Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003302106A 2002-11-21 2003-11-19 New tricyclic angiotensin ii agonists Abandoned AU2003302106A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42793602P 2002-11-21 2002-11-21
US60/427,936 2002-11-21
PCT/GB2003/005037 WO2004046141A1 (en) 2002-11-21 2003-11-19 New tricyclic angiotensin ii agonists

Publications (1)

Publication Number Publication Date
AU2003302106A1 true AU2003302106A1 (en) 2004-06-15

Family

ID=32326616

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003302106A Abandoned AU2003302106A1 (en) 2002-11-21 2003-11-19 New tricyclic angiotensin ii agonists

Country Status (2)

Country Link
AU (1) AU2003302106A1 (en)
WO (1) WO2004046141A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1482931B1 (en) 2002-03-05 2011-10-19 TransTech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
US8067418B2 (en) 2005-04-12 2011-11-29 Vicore Pharma Ab Tricyclic angiotensin II agonists
ES2395194T3 (en) * 2005-04-12 2013-02-11 Vicore Pharma Ab New tricyclic agonists of angiotensin II
JP5179349B2 (en) 2005-04-12 2013-04-10 ヴィコール・ファルマ・アーベー Novel bicyclic angiotensin II agonist
CA2690226C (en) 2007-06-20 2012-07-24 Mitsubishi Tanabe Pharma Corporation Novel malonic acid sulfonamide derivative and pharmaceutical use thereof
US8263630B2 (en) 2008-02-12 2012-09-11 Bristol-Myers Squibb Company 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP5805646B2 (en) 2009-09-30 2015-11-04 ブイティーブイ・セラピューティクス・エルエルシー Substituted imidazole derivatives for the treatment of Alzheimer's disease
WO2015152393A1 (en) 2014-04-03 2015-10-08 国立研究開発法人国立循環器病研究センター Medicine for suppressing malignant tumor metastasis
TW202140422A (en) 2014-10-06 2021-11-01 美商維泰克斯製藥公司 Modulators of cystic fibrosis transmembrane conductance regulator
ES2946970T3 (en) 2016-03-31 2023-07-28 Vertex Pharma Transmembrane conductance regulator of cystic fibrosis modulators
BR112019006213A2 (en) 2016-09-30 2019-06-18 Vertex Pharma cystic fibrosis transmembrane conductance regulator modulator, pharmaceutical compositions, treatment methods and process for making the modulator
RU2632005C1 (en) * 2016-10-10 2017-10-02 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ГБОУ ВПО ВолгГМУ МЗ РФ N-(acetylsalicyloyl)pyrazol with cerebroprotector action in case of cerebral circulation insufficiency
LT3551622T (en) 2016-12-09 2021-02-25 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
TWI668211B (en) * 2017-02-23 2019-08-11 德商拜耳作物科學公司 Method for preparing methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1h-1,2,4-triazol-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylate
MA54105A (en) 2017-06-08 2021-09-15 Vertex Pharma CYSTIC FIBROSIS TREATMENT METHODS
WO2019018395A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3071278A1 (en) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
TWI719349B (en) 2017-10-19 2021-02-21 美商維泰克斯製藥公司 Crystalline forms and compositions of cftr modulators
WO2019113476A2 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (en) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 Pharmaceutical compositions for treating cystic fibrosis
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
GB201913603D0 (en) 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
GB201917327D0 (en) 2019-11-28 2020-01-15 Vicore Pharma Ab New pharmaceutical use
PH12022552413A1 (en) 2020-03-19 2024-01-08 Vicore Pharma Ab Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii
GB202004094D0 (en) 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
GB202013721D0 (en) 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
CA3212900A1 (en) 2021-03-23 2022-09-29 Tomas Fex Selective angiotensin ii receptor ligands
GB202104038D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
GB202104033D0 (en) 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
AU2022306778A1 (en) 2021-07-09 2024-01-18 Vicore Pharma Ab New selective angiotensin ii compounds
WO2023193733A1 (en) * 2022-04-06 2023-10-12 武汉人福创新药物研发中心有限公司 At2r agonist
EP4648850A1 (en) 2023-01-09 2025-11-19 Vicore Pharma AB Selective angiotensin ii compounds
CN119504722A (en) * 2023-08-25 2025-02-25 武汉人福创新药物研发中心有限公司 A thiophenesulfonyl carbamate as AT2R agonist and its use
WO2025146172A1 (en) * 2024-01-03 2025-07-10 武汉人福创新药物研发中心有限公司 Fused ring compound as at2r agonist

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262412A (en) * 1993-03-10 1993-11-16 Merck & Co., Inc. Substituted pyrazoles, compositions and use
YU78601A (en) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-thienylbenzyl)-imidazoles as angiotensin-(1-7) receptor agonists, method for the production and the utilization thereof and pharmaceutical preparations containing said compounds

Also Published As

Publication number Publication date
WO2004046141A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
AU2003302106A1 (en) New tricyclic angiotensin ii agonists
AU2003302027A1 (en) New tricyclic angiotensin ii agonists
AU2003224111A1 (en) Substituted pyrazolo-pyrimidine-4-ones
AU2003232712A1 (en) Novel substituted indoles
WO2003072535A8 (en) Substituted hydroxyethylamines
AU2003238043A1 (en) Substituted imidazotriazines
AU2002951705A0 (en) Reflectometry
AU2003245984A1 (en) Hetero-cyclicaly substituted imidazotriazines
AU2003246992A1 (en) Padlock
AU2003287406A1 (en) Digital-rights management
AU2003219291A1 (en) Bicyclic compounds useful as angiotensin ii agonists
AU2003286251A1 (en) New bicyclic angiotensin ii agonists
AU2003294900A1 (en) Substituted 5-aminomethyl-1h-pyrrole-2-carboxamides
AU2003212366A1 (en) Substituted 4-aminocyclohexanols
AU2003290818A1 (en) Topoisomerase-targeting agents
AU2002952559A0 (en) New use
AUPS044102A0 (en) New compound
AU2003255834A1 (en) Luminescent compounds
AU2003240843A1 (en) Cylinder
AU2003205837A1 (en) Tricyclic compounds useful as angiotensin ii agonists
AU2003100738A4 (en) Lewis stow-a-boat
AU2003253321A1 (en) Luminescent mixtures
AU2002100325A4 (en) Convict - brick trail
AU2002100498A4 (en) Linline
AU2002100508A4 (en) Photocard

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase